Skip to Content
Merck Clinical Trials Logo

Clinical Trials

  • English
  • Español
Merck

Clinical Trials

Merck Clinical Trials Primary

  • About clinical trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs

Condition: Ovarian Neoplasms

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

October 9, 2022

By clique_admin

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors.

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Icon for accessibility